H. Lundbeck A/S (The Lundbeck Foundation)

H. Lundbeck A/S is a global pharmaceutical company dedicated to advancing brain health and transforming lives through the research, development, manufacturing, marketing, and sale of pharmaceuticals. Headquartered in Copenhagen, Denmark, Lundbeck focuses exclusively on brain diseases, aiming to address significant unmet medical needs in this specialized field.

The company's product portfolio targets a wide range of central nervous system (CNS) disorders, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, epilepsy, and migraine. Key products include Abilify Maintena, Rexulti, Brintellix/Trintellix, Northera, Sabril, Onfi, and Vyepti. Lundbeck operates globally, with products registered in over 80 countries, and generates significant sales in North America, Asia, and Europe.

Under the leadership of President and CEO Charl van Zyl, Lundbeck positions itself as a "Focused Innovator" and a "pure-play neuroscience expert." The company recently raised its 2026 sales and earnings growth forecasts, driven by strong U.S. demand for its migraine treatment Vyepti and delayed generic competition for the schizophrenia drug Abilify Maintena. In late 2024, Lundbeck acquired Longboard Pharmaceuticals, Inc. to bolster its neuro-rare disease pipeline with bexicaserin, and in late 2025, it restructured its global operations to a partnership model in certain markets to reallocate resources towards neuro-rare and neuro-specialty diseases.